VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia
Open Access
- 3 August 2006
- journal article
- letter
- Published by Wiley in American Journal of Hematology
- Vol. 81 (12), 987-988
- https://doi.org/10.1002/ajh.20672
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Bortezomib is an efficient agent in plasma cell leukemiasInternational Journal of Cancer, 2004
- A Phase 2 Study of Bortezomib in Relapsed, Refractory MyelomaNew England Journal of Medicine, 2003
- Long‐Term disease‐free survival in a primary plasma cell leukemia treated by VAD, autologous PBSC transplantation, and IFN‐αAmerican Journal of Hematology, 2002
- Plasma cell leukemiaCurrent Treatment Options in Oncology, 2001